This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tschanz, C. Articles by Azarnoff, D. L. Search for Related Content PubMed PubMed Citation Articles by Tschanz, C. Articles by Azarnoff, D. L.

Metabolic Disposition of Antipyrine in Patients with Lung Cancer¹

Departments of Medicine and Pharmacology, Clinical Pharmacology-Toxicology Center, University of Kansas Medical Center, College of Health Sciences, and Hospital, Kansas City, Kansas 66103 [C. T., D. L. A.], and Kansas City Veterans Administration Hospital, Kansas City, Missouri 64128 [C. E. H., D. H. H.]

The metabolism of antipyrine (10 mg/kg i.v.) was studied in nine patients with cancer of the lung and in a cancer-free control group matched for age, sex, drug intake, and smoking and drinking history. The mean plasma clearance of antipyrine was 0.0475 ± 0.009 liter/kg/hr in the tumor group and 0.0557 ± 0.007 liter/kg/hr in the control group (p > 0.05). The antipyrine plasma elimination half-life was longer in the group with tumors (9.5 ± 1.3 hr) compared to the control group (7.7 ± 1.3 hr), but the difference was not statistically significant (p > 0.05). There was no difference between the groups in the excretion of two major antipyrine metabolites, 4-hydroxyantipyrine and N-demethylantipyrine, in a 48-hr urine sample. Thus, the presence of lung cancer in humans does not significantly alter antipyrine elimination.

¹ Supported by Grants GM15956 from USPHS and Medical Research Service, Veterans Administration Hospital.

² To whom requests for reprints should be addressed, at the University of Kansas Medical Center, Kansas City, Kans. 66103.

Received 5/ 4/77. Accepted 7/22/77.